Drugs / Ilitacan
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT06368063 Comparator | May 2024 → Mar 2026 overdue | pancreas disorder | Xi'an Jiaotong University | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ilitacan | “Ilitacan 150mg/m\^2 intravenous infusion for more than 30-90 minutes, day 1” NCT06368063 ↗ |
| Route | Intravenous | “Ilitacan 150mg/m\^2 intravenous infusion for more than 30-90 minutes, day 1” NCT06368063 ↗ |